Strontium-89: a desirable therapeutic for bone metastases of prostate cancer.
- Author:
Yu-Bo MA
1
;
Wei-Li YAN
;
Ji-Can DAI
;
Feng XU
;
Qi YUAN
;
He-Hai SHI
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Bone Neoplasms; radiotherapy; secondary; Follow-Up Studies; Humans; Male; Middle Aged; Pain, Intractable; radiotherapy; Prostatic Neoplasms; pathology; Strontium Radioisotopes; therapeutic use; Treatment Outcome
- From: National Journal of Andrology 2008;14(9):819-822
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of strontium-89 (89Sr) in the treatment of painful bone metastases of prostate cancer.
METHODSA total of 116 patients with painful bone metastases of prostate cancer received bilateral orchiectomy and incretion, followed by intravenous injection of 89Sr at the dose of 1.48-2.22 MBq (40-60 microCi)/kg. The clinical effects were evaluated by follow-up analysis.
RESULTSAfter the 89Sr treatment, appetite and sleep were evidently improved in 33.6% and 56.0% of the patients respectively, the applied dose of anodyne reduced in 61.2%, pain alleviated in 83.6%, with an absolute palliation rate of 24.1%. Pain relief started at 3-21 (10.2 +/- 6.5) days and lasted 3-12 (5.3 +/- 2.2) months. Flare ache occurred in 31.9% of the patients. Compared with pre-treatment, the mean score on Karnofsky's performance status (KPS) was 20.0% higher, and the WBC count decreased to 3.0-3.9 x 10(6)/L in 18.1% of the patients. Whole body bone scintigraphy of 53 followed-up patients showed that 39 (73.6%) of them exhibited an obvious decrease in the number of metastases, 10 (18.9% remained in a stabilized state and only 4 (7.5% deteriorated.
CONCLUSION89Sr, capable of inhibiting bone metastasis, palliating pain and improving the quality of life with few adverse effects, can be used as a desirable therapeutic for painful bone metastases of prostate cancer.
